1Y Target$34.83Near-term target
5Y Target$51.89Compound horizon
10Y Target$135.03Long-dated conviction
FCF—TTM—FCF not applicable for this sector (bank / insurer / REIT) or data unavailable
Rev-92.9%FY2012 YoYFRevenue -92.9% — severe decline · Computed from last two annual revenue figures (FY2012 YoY).
D/E0.02totalAD/E 0.02 — essentially debt-free, pristine balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
PEG—proxy—PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Pharmaceuticals · market cap $12.8b. Down 69% from 52-week high of $83.60 — deep drawdown territory. Revenue -93% — in contraction; any catalyst that reverses this triggers re-rating.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Revenue contracting -93% — the operational turn is not yet visible in the top line. Down 69% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.89 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon
1-3 yr $34.83 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $51.89 — requires the platform / technology to reach commercial scale. 10 yr $135.03 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.